Corcept Therapeutics Incorporated Cash Flow-to-Debt Ratio
Corcept Therapeutics Incorporated cash flow-to-debt ratio. Corcept Therapeutics Incorporated (CORT) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of $-16.77 Million could theoretically repay 0% of its total liabilities ($176.89 Million) in one year. Check Corcept Therapeutics Incorporated cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Corcept Therapeutics Incorporated (2003–2025)
Cash flow-to-debt ratio of Corcept Therapeutics Incorporated from 2003 to 2025. Historical debt coverage capacity for Corcept Therapeutics Incorporated across 23 annual periods. Check CORT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Corcept Therapeutics Incorporated Cash Flow-to-Debt Ratio by Year (2003–2025)
Corcept Therapeutics Incorporated cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Corcept Therapeutics Incorporated. For the full cash flow conversion analysis, see how efficiently does Corcept Therapeutics Incorporated generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.75x | $142.00 Million | $188.85 Million | ▼ -38.9% |
| 2024 | 1.23x | $198.07 Million | $160.96 Million | ▲ +11.2% |
| 2023 | 1.11x | $127.04 Million | $114.81 Million | ▼ -25.0% |
| 2022 | 1.47x | $120.32 Million | $81.59 Million | ▼ -57.9% |
| 2021 | 3.50x | $167.89 Million | $47.95 Million | ▲ +11.5% |
| 2020 | 3.14x | $151.97 Million | $48.39 Million | ▼ -5.1% |
| 2019 | 3.31x | $136.12 Million | $41.13 Million | ▲ +2.5% |
| 2018 | 3.23x | $115.67 Million | $35.81 Million | ▲ +56.7% |
| 2017 | 2.06x | $60.94 Million | $29.57 Million | ▲ +206.7% |
| 2016 | 0.67x | $18.39 Million | $27.37 Million | ▲ +617.8% |
| 2015 | 0.09x | $3.13 Million | $33.44 Million | ▲ +113.0% |
| 2014 | -0.72x | $-27.38 Million | $38.02 Million | ▲ +18.3% |
| 2013 | -0.88x | $-37.06 Million | $42.06 Million | ▲ +8.5% |
| 2012 | -0.96x | $-36.02 Million | $37.39 Million | ▲ +82.3% |
| 2011 | -5.45x | $-27.40 Million | $5.03 Million | ▲ +5.6% |
| 2010 | -5.77x | $-22.29 Million | $3.86 Million | ▲ +22.3% |
| 2009 | -7.43x | $-17.97 Million | $2.42 Million | ▼ -16.0% |
| 2008 | -6.40x | $-18.36 Million | $2.87 Million | ▼ -75.8% |
| 2007 | -3.64x | $-10.96 Million | $3.01 Million | ▲ +44.5% |
| 2006 | -6.56x | $-23.24 Million | $3.54 Million | ▼ -35.6% |
| 2005 | -4.84x | $-17.23 Million | $3.56 Million | ▲ +35.7% |
| 2004 | -7.52x | $-13.72 Million | $1.82 Million | ▼ -15.6% |
| 2003 | -6.51x | $-10.00 Million | $1.54 Million | — |